Glioblastoma

Glioblastoma, also known historically as glioblastoma multiforme (GBM), is the most common and most malignant primary brain tumor in adults. It is classified as a grade IV astrocytoma by the World Health Organization (WHO), the highest possible grade, reflecting its rapid growth and poor prognosis. These tumors are characterized by their diffuse, finger-like infiltration into surrounding healthy brain tissue, which makes complete surgical removal virtually impossible. Microscopically, glioblastomas exhibit significant cellular diversity, necrosis (tissue death), and extensive blood vessel growth (angiogenesis), which fuels their aggressive expansion.

The symptoms of glioblastoma are often nonspecific and depend heavily on the tumor's size and location within the brain. Common initial signs include persistent headaches, seizures, nausea, and vomiting. As the tumor grows and exerts pressure on brain structures, patients may develop more specific neurological deficits, such as weakness on one side of the body, memory loss, personality changes, or difficulties with speech and vision. The rapid onset and progression of these symptoms typically lead to diagnosis within a few months.

Glioblastoma belongs to a broader category of tumors called gliomas, which originate from the glial (supportive) cells of the central nervous system. It can arise in two ways: as a primary tumor, which appears de novo without evidence of a pre-existing, lower-grade lesion, or as a secondary tumor, which evolves from a less aggressive grade II or III astrocytoma. Primary glioblastoma is the more common form, accounting for over 90% of cases, and typically affects older adults. The standard treatment approach, often called the Stupp protocol, involves maximal safe surgical resection to remove as much of the tumor as possible, followed by a combination of radiation therapy and chemotherapy with the alkylating agent temozolomide.

For patients and their families, a glioblastoma diagnosis is devastating due to its aggressive nature and challenging prognosis. Despite multimodal therapy, the median survival time is approximately 15-18 months, with a five-year survival rate of less than 10%. The tumor's resistance to treatment is a major clinical challenge, stemming from several factors: the protective blood-brain barrier, which limits the delivery of chemotherapy drugs to the brain; the tumor's infiltrative growth pattern; and its profound genetic and cellular heterogeneity, which allows it to evade therapies and quickly recur. Consequently, glioblastoma remains an area of intense scientific research, with ongoing efforts focused on developing novel treatments such as immunotherapy, targeted molecular therapies, and innovative devices like tumor-treating fields, all aimed at improving survival and quality of life for patients with this formidable disease.